Parmax Pharma Limited reported un-audited standalone earnings results for the first quarter ended June 30, 2017. For the quarter, the company reported total income from operation of INR 26,262,593 compared to INR 150,000, loss from operations before exceptional items and tax of INR 2,091,512 compared to INR 41,040, loss before tax of INR 2,091,512 compared to INR 41,040 and net loss of INR 2,091,512 or INR 0.56 per basic share compared to INR 41,040 for the last year.